FDA spurns Lilly, Boehringer diabetes drug, cites factory problem
March 5 (Reuters) - Eli Lilly and Co and partner Boehringer Ingelheim said U.S. regulators have declined to approve their experimental diabetes drug empagliflozin, citing previously observed deficiencies at a manufacturing facility where it would be made.
The drugmakers, in a joint release on Wednesday, said the U.S. Food and Drug Administration determined that deficiencies at the Boehringer Ingelheim factory would have to be resolved before the product could be approved.
- China food scandal spreads, drags in Starbucks, Burger King and McNuggets in Japan |
- U.S. courts deliver conflicting rulings on Obama health care law
- Israel pounds Gaza despite international peace efforts |
- EU readies possible capital, tech sanctions on Russia
- Train carrying MH17 bodies on final journey reaches Ukraine city |